Drugs / IAE0972
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05396339 | Jun 2022 → May 2024 | cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06719479 | Jan 2025 → Jan 2028 expected | head and neck squamous cell carcinoma, metastatic squamous cell carcinoma | SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IAE0972 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06719479 ↗ |
| Route | Intravenous | “IAE0972 is infused intravenously” NCT06719479 ↗ |